All In Biotech

Drug Trial Radar · NCT06508931

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

Aug 4, 2025

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Miltenyi Biomedicine GmbHIndustry
Sponsor type
Industry
Collaborators
PPD, Part of Thermo Fisher Scientific
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.

Conditions

  • B-Cell Neoplasm

Interventions

  • zamtocabtagene autoleucel (MB-CART2019.1)Drug

    Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BORR, Best Overall Response RateTime frame: From infusion until week 78
  2. Type, frequency, and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) [Safety and toxicity of the study product]Time frame: From infusion until week 78

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hôpital Robert Debré

    Paris, Boulevard Sérurier 48, France · Active not recruiting

  • Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie

    Münster, Albert-Schweitzer-Campus 1, Gebaeude A1, Germany · Active not recruiting

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Rome, Piazza Sant Onofrio 4, Italy · Recruiting

  • Prinses Maxima Centrum

    Utrecht, Heidelberglaan 25, Netherlands · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.